Table 3.
Subgroup results for ARM oncological safety.
| Stratification criterion | Number of studies | Pooled results (95%CI) | I2 | P - value for difference | |
|---|---|---|---|---|---|
| SLN-ARM crossover rate | Overall | 11 | 12%(6%–19%) | 93.7% | <0.05 |
| Mapping materials: | |||||
| - Blue dye | 7 | 10%(5%–17%) | 81.1% | <0.05 | |
| - Blue dye and fluorescence | 3 | 21%(15%–28%) | – | – | |
| - Blue dye and radioisotope | 1 | 4%(3%–6%) | – | – | |
| Geographical region: | |||||
| - Asia | 5 | 19%(12%–26%) | 84% | <0.05 | |
| - America | 4 | 6%(3%–9%) | 71.6% | 0.01 | |
| - Europe | 1 | 14%(2%–43%) | – | – | |
| - Australia |
1 |
9%(2%–25%) |
– |
– |
|
| Stratification criterion | Number of studies | Pooled results (95%CI) | I2 | P - value for difference | |
| Overall resected ARM metastatic rate | Overall | 27 | 13%(10%–17%) | 75.4% | <0.05 |
| Mapping materials: | |||||
| - Blue dye | 17 | 13%(9%–18%) | 42.8% | 0.03 | |
| - Fluorescence | 1 | 22%(14%–33%) | – | – | |
| - Radioisotope | 2 | 26%(21%–32%) | – | – | |
| - Blue dye and fluorescence | 3 | 13%(4%–26%) | – | – | |
| - Blue dye and radioisotope | 4 | 10%(7%–14%) | 8.4% | 0.35 | |
| Geographical region: | |||||
| - Asia | 10 | 14%(9%–19%) | 75.9% | <0.05 | |
| - America | 6 | 12%(7%–19%) | 32.9% | 0.19 | |
| - Europe | 9 | 13%(6%–21%) | 73.6% | <0.05 | |
| - Australia | 1 | 27%(17%–39%) | – | – | |
| - Africa |
1 |
0%(0%–60%) |
– |
– |
|
| Stratification criterion | Number of studies | Pooled results (95%CI) | I2 | P - value for difference | |
| SLN+ARM metastatic rate | Overall | 5 | 22%(13%–33%) | 22.8% | 0.269 |
| Mapping materials | |||||
| - Blue dye | 3 | 18%(4%–37%) | – | – | |
| - Radioisotope | 1 | 21%(9%–39%) | – | – | |
| - Blue dye and fluorescence | 1 | 33%(15%–57%) | – | – | |
| Geographical region: | |||||
| - Asia | 2 | 33%(19%–49%) | – | – | |
| - America | 1 | 18%(2%–52%) | – | – | |
| - Europe | 1 | 21%(9%–39%) | – | – | |
| - Australia |
1 |
6%(0%–30%) |
– |
– |
|
| Stratification criterion | Number of studies | Pooled results (95%CI) | I2 | P - value for difference | |
| CP-N+ARM metastatic rate | Overall | 2 | 30%(17%–45%) | – | – |